PRODUCT PIPELINE


HOME > PRODUCT PIPELINE
PRODUCT PIPELINE

YZY Biopharma has established proprietary bispecific antibody platform and developed a series of bispecific antibody drug candidates for immunotherapeutics. Our core technology of making bispecific antibody is at the cutting edge of antibody engineering and biologics.  Our cancer treatment YBODY® is multi functional and capable of binding both TAA and human immune cells.  In addition to recognizing, inhibiting and killing tumor cells, YBODY® can stimulate human immune system, increase cytotoxicity towards tumor cells, and inhibit tumor relapse and dissemination. Most importantly, YBODY® has demonstrated high potency and stability. 

 

YZY Biopharma has solid and diverse pipeline based on YBODY® platform.  The two most advanced programs have entered CDE review and are expected to be approved in the nearest future.  M802 is ananti-Her2/anti-CD3 bispecific antibody.  Intended disease indications include Her2 positive breast and gastric cancers.  In addition to possessing same MOA as Herceptin, M802 is designed to stimulate T cells with anti-CD3 moiety in the molecule.  In comparison with Herceptin, M802 is proven to be more efficacious, more potent and have better safety profile.  M701 is an anti-EpCAM and anti-CD3 bispecific antibody with treatment areas including tumor induced ascites.  M701 has been proven to be much better than approved drug Removab,which is also an anti-EpCAM and anti-CD3 bispecific antibody.  M701 has low immunogenicity and offers patients a low cost and efficacious option. Our early discovery pipeline is rich with candidates for diverse types of cancers.  They include anti-PD-L1xantiCD3  bsAb for small cell lung cancer,melanoma), anti-CD19xanti-CD3 bsAb for ALL, anti-CDXxantiCD3 for MM,anti-CD133xanti-CD3 for colorectal cancer, anti-EMP2xanti-CD3 for ovarian cancer.   


Target Screening Antibody Engineering Pharmacology CMC Pre-clinical IND Phaes I Phaes II Phaes III
M802(Her2/CD3):
Breast cancer, Gastric cancer
M701(EpCAM/CD3):
Malignant ascites due to colorectal cancer, ovarian cancer and liver cancer
PD-L1/CD3:
NSCLC,Melanoma etc.
CD19/CD3:
Lymphoma
CDX /CD3:
Myeloma
CD133/CD3:
Colon cancer
EMP2/CD3:
Ovarian Cancer
EGFR/CD3:
Colon cancer
Others
“Significant New Drugs Development” ,the first for IND in chinaNational Natural Science Foundation of China